Use of Corticosteroids in a Population-Based Cohort of Boys With Duchenne and Becker Muscular Dystrophy
The use of corticosteroids for treatment of Duchenne and Becker muscular dystrophy in clinical practice from 1991 through 2005 was reviewed in a large population-based cohort (MD STARnet) of boys in 4 regional sites and 6 clinics of the United States. Corticosteroid use increased from 20% (11 of 56...
Gespeichert in:
| Veröffentlicht in: | Journal of child neurology 2010-11, Vol.25 (11), p.1319-1324 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1324 |
|---|---|
| container_issue | 11 |
| container_start_page | 1319 |
| container_title | Journal of child neurology |
| container_volume | 25 |
| creator | Matthews, Dennis J. James, Katherine A. Miller, Lisa A. Pandya, Shree Campbell, Kimberly A. Ciafaloni, Emma Mathews, Katherine D. Miller, Timothy M. Cunniff, Christopher Meaney, F. John Druschel, Charlotte M. Romitti, Paul A. Fox, Deborah J. |
| description | The use of corticosteroids for treatment of Duchenne and Becker muscular dystrophy in clinical practice from 1991 through 2005 was reviewed in a large population-based cohort (MD STARnet) of boys in 4 regional sites and 6 clinics of the United States. Corticosteroid use increased from 20% (11 of 56 individuals) in 1991 to 44% (93 of 218 individuals) in 2005. Average use varied by site and ranged from 15% to 49%. The median age of corticosteroid initiation was 6.9 years (range, 3.7-17.4 years). Dosage and growth information was available for 102 participants and showed a median dose as 0.729 mg/kg for prednisone and 0.831 mg/kg for deflazacort. T. The most common reasons that corticosteroids were discontinued included weight gain, behavioral side effects, and loss of ambulation, resulting in full-time wheelchair use. Substantial variations in clinical practice were identified among study sites. |
| doi_str_mv | 10.1177/0883073810362762 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5882203</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0883073810362762</sage_id><sourcerecordid>954612614</sourcerecordid><originalsourceid>FETCH-LOGICAL-c491t-e2a0f2d1f2982060972a24889855077e636af7e16bda0f768159d60b5cd405253</originalsourceid><addsrcrecordid>eNqFkc1v1DAQxS1ERZfCnRPyjVPo2Ik_ckFit3xJrdoDFUfL60w2Lll7sZNK-9_j1ZYKkBCnObzfe5qZR8grBm8ZU-octK5B1ZpBLbmS_AlZMAW60lzXT8niIFcH_ZQ8z_kOALRo4Rk55cBBSQYLsrnNSGNPVzFN3sU8YYq-y9QHaulN3M2jnXwM1dJm7Ao1FO7AL-M-029-GujF7AYMAakNHV2i-46JXs3ZFWeiF_s8pbgb9i_ISW_HjC8f5hm5_fjh6-pzdXn96cvq_WXlmpZNFXILPe9Yz1vNQUKruOWN1q0WApRCWUvbK2Ry3RVQSc1E20lYC9c1ILioz8i7Y-5uXm-xcximZEezS35r095E682fSvCD2cR7I7TmHOoS8OYhIMUfM-bJbH12OI42YJyzaUUjGZes-S-ptIIGpGoLCUfSpZhzwv5xHwbmUKT5u8hief37HY-GX80VoDoC2W7Q3MU5hfLXfwf-BMqKpVQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>787040679</pqid></control><display><type>article</type><title>Use of Corticosteroids in a Population-Based Cohort of Boys With Duchenne and Becker Muscular Dystrophy</title><source>MEDLINE</source><source>SAGE Journals</source><creator>Matthews, Dennis J. ; James, Katherine A. ; Miller, Lisa A. ; Pandya, Shree ; Campbell, Kimberly A. ; Ciafaloni, Emma ; Mathews, Katherine D. ; Miller, Timothy M. ; Cunniff, Christopher ; Meaney, F. John ; Druschel, Charlotte M. ; Romitti, Paul A. ; Fox, Deborah J.</creator><creatorcontrib>Matthews, Dennis J. ; James, Katherine A. ; Miller, Lisa A. ; Pandya, Shree ; Campbell, Kimberly A. ; Ciafaloni, Emma ; Mathews, Katherine D. ; Miller, Timothy M. ; Cunniff, Christopher ; Meaney, F. John ; Druschel, Charlotte M. ; Romitti, Paul A. ; Fox, Deborah J. ; MD STARnet</creatorcontrib><description>The use of corticosteroids for treatment of Duchenne and Becker muscular dystrophy in clinical practice from 1991 through 2005 was reviewed in a large population-based cohort (MD STARnet) of boys in 4 regional sites and 6 clinics of the United States. Corticosteroid use increased from 20% (11 of 56 individuals) in 1991 to 44% (93 of 218 individuals) in 2005. Average use varied by site and ranged from 15% to 49%. The median age of corticosteroid initiation was 6.9 years (range, 3.7-17.4 years). Dosage and growth information was available for 102 participants and showed a median dose as 0.729 mg/kg for prednisone and 0.831 mg/kg for deflazacort. T. The most common reasons that corticosteroids were discontinued included weight gain, behavioral side effects, and loss of ambulation, resulting in full-time wheelchair use. Substantial variations in clinical practice were identified among study sites.</description><identifier>ISSN: 0883-0738</identifier><identifier>EISSN: 1708-8283</identifier><identifier>DOI: 10.1177/0883073810362762</identifier><identifier>PMID: 20207610</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adolescent ; Adrenal Cortex Hormones - adverse effects ; Adrenal Cortex Hormones - therapeutic use ; Age ; Becker's muscular dystrophy ; Child ; Child, Preschool ; Corticoids ; Humans ; Male ; Muscular Dystrophy, Duchenne - drug therapy ; Prednisone ; Reviews ; Side effects ; United States ; Weight Gain - drug effects</subject><ispartof>Journal of child neurology, 2010-11, Vol.25 (11), p.1319-1324</ispartof><rights>The Author(s) 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c491t-e2a0f2d1f2982060972a24889855077e636af7e16bda0f768159d60b5cd405253</citedby><cites>FETCH-LOGICAL-c491t-e2a0f2d1f2982060972a24889855077e636af7e16bda0f768159d60b5cd405253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0883073810362762$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0883073810362762$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>230,314,776,780,881,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20207610$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matthews, Dennis J.</creatorcontrib><creatorcontrib>James, Katherine A.</creatorcontrib><creatorcontrib>Miller, Lisa A.</creatorcontrib><creatorcontrib>Pandya, Shree</creatorcontrib><creatorcontrib>Campbell, Kimberly A.</creatorcontrib><creatorcontrib>Ciafaloni, Emma</creatorcontrib><creatorcontrib>Mathews, Katherine D.</creatorcontrib><creatorcontrib>Miller, Timothy M.</creatorcontrib><creatorcontrib>Cunniff, Christopher</creatorcontrib><creatorcontrib>Meaney, F. John</creatorcontrib><creatorcontrib>Druschel, Charlotte M.</creatorcontrib><creatorcontrib>Romitti, Paul A.</creatorcontrib><creatorcontrib>Fox, Deborah J.</creatorcontrib><creatorcontrib>MD STARnet</creatorcontrib><title>Use of Corticosteroids in a Population-Based Cohort of Boys With Duchenne and Becker Muscular Dystrophy</title><title>Journal of child neurology</title><addtitle>J Child Neurol</addtitle><description>The use of corticosteroids for treatment of Duchenne and Becker muscular dystrophy in clinical practice from 1991 through 2005 was reviewed in a large population-based cohort (MD STARnet) of boys in 4 regional sites and 6 clinics of the United States. Corticosteroid use increased from 20% (11 of 56 individuals) in 1991 to 44% (93 of 218 individuals) in 2005. Average use varied by site and ranged from 15% to 49%. The median age of corticosteroid initiation was 6.9 years (range, 3.7-17.4 years). Dosage and growth information was available for 102 participants and showed a median dose as 0.729 mg/kg for prednisone and 0.831 mg/kg for deflazacort. T. The most common reasons that corticosteroids were discontinued included weight gain, behavioral side effects, and loss of ambulation, resulting in full-time wheelchair use. Substantial variations in clinical practice were identified among study sites.</description><subject>Adolescent</subject><subject>Adrenal Cortex Hormones - adverse effects</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Age</subject><subject>Becker's muscular dystrophy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Corticoids</subject><subject>Humans</subject><subject>Male</subject><subject>Muscular Dystrophy, Duchenne - drug therapy</subject><subject>Prednisone</subject><subject>Reviews</subject><subject>Side effects</subject><subject>United States</subject><subject>Weight Gain - drug effects</subject><issn>0883-0738</issn><issn>1708-8283</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1v1DAQxS1ERZfCnRPyjVPo2Ik_ckFit3xJrdoDFUfL60w2Lll7sZNK-9_j1ZYKkBCnObzfe5qZR8grBm8ZU-octK5B1ZpBLbmS_AlZMAW60lzXT8niIFcH_ZQ8z_kOALRo4Rk55cBBSQYLsrnNSGNPVzFN3sU8YYq-y9QHaulN3M2jnXwM1dJm7Ao1FO7AL-M-029-GujF7AYMAakNHV2i-46JXs3ZFWeiF_s8pbgb9i_ISW_HjC8f5hm5_fjh6-pzdXn96cvq_WXlmpZNFXILPe9Yz1vNQUKruOWN1q0WApRCWUvbK2Ry3RVQSc1E20lYC9c1ILioz8i7Y-5uXm-xcximZEezS35r095E682fSvCD2cR7I7TmHOoS8OYhIMUfM-bJbH12OI42YJyzaUUjGZes-S-ptIIGpGoLCUfSpZhzwv5xHwbmUKT5u8hief37HY-GX80VoDoC2W7Q3MU5hfLXfwf-BMqKpVQ</recordid><startdate>20101101</startdate><enddate>20101101</enddate><creator>Matthews, Dennis J.</creator><creator>James, Katherine A.</creator><creator>Miller, Lisa A.</creator><creator>Pandya, Shree</creator><creator>Campbell, Kimberly A.</creator><creator>Ciafaloni, Emma</creator><creator>Mathews, Katherine D.</creator><creator>Miller, Timothy M.</creator><creator>Cunniff, Christopher</creator><creator>Meaney, F. John</creator><creator>Druschel, Charlotte M.</creator><creator>Romitti, Paul A.</creator><creator>Fox, Deborah J.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>5PM</scope></search><sort><creationdate>20101101</creationdate><title>Use of Corticosteroids in a Population-Based Cohort of Boys With Duchenne and Becker Muscular Dystrophy</title><author>Matthews, Dennis J. ; James, Katherine A. ; Miller, Lisa A. ; Pandya, Shree ; Campbell, Kimberly A. ; Ciafaloni, Emma ; Mathews, Katherine D. ; Miller, Timothy M. ; Cunniff, Christopher ; Meaney, F. John ; Druschel, Charlotte M. ; Romitti, Paul A. ; Fox, Deborah J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c491t-e2a0f2d1f2982060972a24889855077e636af7e16bda0f768159d60b5cd405253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adolescent</topic><topic>Adrenal Cortex Hormones - adverse effects</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Age</topic><topic>Becker's muscular dystrophy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Corticoids</topic><topic>Humans</topic><topic>Male</topic><topic>Muscular Dystrophy, Duchenne - drug therapy</topic><topic>Prednisone</topic><topic>Reviews</topic><topic>Side effects</topic><topic>United States</topic><topic>Weight Gain - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matthews, Dennis J.</creatorcontrib><creatorcontrib>James, Katherine A.</creatorcontrib><creatorcontrib>Miller, Lisa A.</creatorcontrib><creatorcontrib>Pandya, Shree</creatorcontrib><creatorcontrib>Campbell, Kimberly A.</creatorcontrib><creatorcontrib>Ciafaloni, Emma</creatorcontrib><creatorcontrib>Mathews, Katherine D.</creatorcontrib><creatorcontrib>Miller, Timothy M.</creatorcontrib><creatorcontrib>Cunniff, Christopher</creatorcontrib><creatorcontrib>Meaney, F. John</creatorcontrib><creatorcontrib>Druschel, Charlotte M.</creatorcontrib><creatorcontrib>Romitti, Paul A.</creatorcontrib><creatorcontrib>Fox, Deborah J.</creatorcontrib><creatorcontrib>MD STARnet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of child neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matthews, Dennis J.</au><au>James, Katherine A.</au><au>Miller, Lisa A.</au><au>Pandya, Shree</au><au>Campbell, Kimberly A.</au><au>Ciafaloni, Emma</au><au>Mathews, Katherine D.</au><au>Miller, Timothy M.</au><au>Cunniff, Christopher</au><au>Meaney, F. John</au><au>Druschel, Charlotte M.</au><au>Romitti, Paul A.</au><au>Fox, Deborah J.</au><aucorp>MD STARnet</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Corticosteroids in a Population-Based Cohort of Boys With Duchenne and Becker Muscular Dystrophy</atitle><jtitle>Journal of child neurology</jtitle><addtitle>J Child Neurol</addtitle><date>2010-11-01</date><risdate>2010</risdate><volume>25</volume><issue>11</issue><spage>1319</spage><epage>1324</epage><pages>1319-1324</pages><issn>0883-0738</issn><eissn>1708-8283</eissn><abstract>The use of corticosteroids for treatment of Duchenne and Becker muscular dystrophy in clinical practice from 1991 through 2005 was reviewed in a large population-based cohort (MD STARnet) of boys in 4 regional sites and 6 clinics of the United States. Corticosteroid use increased from 20% (11 of 56 individuals) in 1991 to 44% (93 of 218 individuals) in 2005. Average use varied by site and ranged from 15% to 49%. The median age of corticosteroid initiation was 6.9 years (range, 3.7-17.4 years). Dosage and growth information was available for 102 participants and showed a median dose as 0.729 mg/kg for prednisone and 0.831 mg/kg for deflazacort. T. The most common reasons that corticosteroids were discontinued included weight gain, behavioral side effects, and loss of ambulation, resulting in full-time wheelchair use. Substantial variations in clinical practice were identified among study sites.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>20207610</pmid><doi>10.1177/0883073810362762</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0883-0738 |
| ispartof | Journal of child neurology, 2010-11, Vol.25 (11), p.1319-1324 |
| issn | 0883-0738 1708-8283 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5882203 |
| source | MEDLINE; SAGE Journals |
| subjects | Adolescent Adrenal Cortex Hormones - adverse effects Adrenal Cortex Hormones - therapeutic use Age Becker's muscular dystrophy Child Child, Preschool Corticoids Humans Male Muscular Dystrophy, Duchenne - drug therapy Prednisone Reviews Side effects United States Weight Gain - drug effects |
| title | Use of Corticosteroids in a Population-Based Cohort of Boys With Duchenne and Becker Muscular Dystrophy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T17%3A30%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Corticosteroids%20in%20a%20Population-Based%20Cohort%20of%20Boys%20With%20Duchenne%20and%20Becker%20Muscular%20Dystrophy&rft.jtitle=Journal%20of%20child%20neurology&rft.au=Matthews,%20Dennis%20J.&rft.aucorp=MD%20STARnet&rft.date=2010-11-01&rft.volume=25&rft.issue=11&rft.spage=1319&rft.epage=1324&rft.pages=1319-1324&rft.issn=0883-0738&rft.eissn=1708-8283&rft_id=info:doi/10.1177/0883073810362762&rft_dat=%3Cproquest_pubme%3E954612614%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=787040679&rft_id=info:pmid/20207610&rft_sage_id=10.1177_0883073810362762&rfr_iscdi=true |